AR127311A1 - NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2 - Google Patents
NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2Info
- Publication number
- AR127311A1 AR127311A1 ARP220102740A ARP220102740A AR127311A1 AR 127311 A1 AR127311 A1 AR 127311A1 AR P220102740 A ARP220102740 A AR P220102740A AR P220102740 A ARP220102740 A AR P220102740A AR 127311 A1 AR127311 A1 AR 127311A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- formula
- artificial nucleic
- cov
- sars
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 title abstract 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title 1
- 229940023146 nucleic acid vaccine Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 108020004707 nucleic acids Proteins 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 7
- 150000007523 nucleic acids Chemical class 0.000 abstract 7
- 150000002632 lipids Chemical class 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 108700021021 mRNA Vaccine Proteins 0.000 abstract 1
- 229940126582 mRNA vaccine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
Abstract
Moléculas de ácido nucleico terapéutico para gestionar, prevenir y/o tratar enfermedades infecciosas causadas por el coronavirus. También composiciones terapéuticas, que incluyen vacunas y nanopartículas lipídicas, que comprenden los ácidos nucleicos terapéuticos y los métodos y usos terapéuticos relacionados. En particular, vacunas de ARNm basadas en secuencias derivadas de la cepa delta del SARS-CoV-2. Reivindicación 1: Un ácido nucleico artificial caracterizado porque comprende una secuencia de nucleótidos codificante que codifica el dominio de unión al receptor (RBD) de la proteína de la espícula (S) de la cepa delta del SARS-CoV-2, o un fragmento de la misma, en donde el RBD consiste, consiste esencialmente o comprende la secuencia de aminoácidos establecida en SEQ ID Nº 60. Reivindicación 11: Un vector caracterizado porque comprende el ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10. Reivindicación 12: Una célula caracterizada porque comprende el ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10 o el vector de la reivindicación 11. Reivindicación 13: Una composición farmacéutica caracterizada porque comprende el ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10 y al menos un primer lípido, en donde el primer lípido es un compuesto de acuerdo con la fórmula (01-I) o (01-II); o un compuesto enumerado en la Tabla 01-1; o un compuesto de acuerdo con la fórmula (02-I); o un compuesto enumerado en la Tabla 02-1; o un compuesto de acuerdo con la fórmula (03-I); o un compuesto enumerado en la Tabla 03-1; o un compuesto de acuerdo con la fórmula (04-I); o un compuesto enumerado en la Tabla 04-1. Reivindicación 17: Un método para gestionar, prevenir o tratar una enfermedad infecciosa causada por coronavirus en un sujeto, caracterizado porque comprende administrar al sujeto una cantidad terapéuticamente eficaz del ácido nucleico artificial de cualquiera de las reivindicaciones 1 a 10, o la composición de cualquiera de las reivindicaciones 13 a 16.Therapeutic nucleic acid molecules to manage, prevent and/or treat infectious diseases caused by coronavirus. Also therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses. In particular, mRNA vaccines based on sequences derived from the delta strain of SARS-CoV-2. Claim 1: An artificial nucleic acid characterized in that it comprises a coding nucleotide sequence that encodes the receptor binding domain (RBD) of the spike (S) protein of the delta strain of SARS-CoV-2, or a fragment of the same, wherein the RBD consists, essentially consists of or comprises the amino acid sequence set forth in SEQ ID NO: 60. Claim 11: A vector characterized in that it comprises the artificial nucleic acid of any of claims 1 to 10. Claim 12: A cell characterized in that it comprises the artificial nucleic acid of any of claims 1 to 10 or the vector of claim 11. Claim 13: A pharmaceutical composition characterized in that it comprises the artificial nucleic acid of any of claims 1 to 10 and at least one first lipid , wherein the first lipid is a compound according to the formula (01-I) or (01-II); or a compound listed in Table 01-1; or a compound according to the formula (02-I); or a compound listed in Table 02-1; or a compound according to the formula (03-I); or a compound listed in Table 03-1; or a compound according to the formula (04-I); or a compound listed in Table 04-1. Claim 17: A method of managing, preventing or treating an infectious disease caused by coronavirus in a subject, characterized in that it comprises administering to the subject a therapeutically effective amount of the artificial nucleic acid of any of claims 1 to 10, or the composition of any of claims 13 to 16.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021122702 | 2021-10-08 | ||
CN2022118782 | 2022-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127311A1 true AR127311A1 (en) | 2024-01-10 |
Family
ID=85803170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220102740A AR127311A1 (en) | 2021-10-08 | 2022-10-06 | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN117083291A (en) |
AR (1) | AR127311A1 (en) |
WO (1) | WO2023056913A1 (en) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11141476B2 (en) * | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
US20200054737A1 (en) * | 2017-04-26 | 2020-02-20 | Modema TX, Inc. | Herpes simplex virus vaccine |
WO2021160346A1 (en) * | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
CN111393532B (en) * | 2020-02-26 | 2021-10-12 | 北京丹大生物技术有限公司 | Novel coronavirus dominant epitope fusion protein, diagnostic reagent and application |
CN111218458B (en) * | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | mRNAs encoding SARS-CoV-2 virus antigen and vaccine and preparation method of vaccine |
CN113151312B (en) * | 2020-03-02 | 2022-12-09 | 中国科学院微生物研究所 | Novel coronavirus SARS-CoV-2mRNA vaccine and its preparation method and application |
US20230285539A1 (en) * | 2020-03-06 | 2023-09-14 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccines against sars-cov-2 and other coronaviruses |
CN113018449B (en) * | 2021-05-14 | 2021-09-07 | 苏州艾博生物科技有限公司 | Cationic lipid compounds, compositions containing the same and uses thereof |
CN112979483B (en) * | 2021-05-14 | 2021-08-06 | 苏州艾博生物科技有限公司 | Cationic lipid compound, composition containing same and application |
CN113046369B (en) * | 2021-05-24 | 2021-08-10 | 中国科学院微生物研究所 | Novel mRNA vaccine of coronavirus |
-
2022
- 2022-10-06 AR ARP220102740A patent/AR127311A1/en unknown
- 2022-10-07 WO PCT/CN2022/123720 patent/WO2023056913A1/en active Application Filing
- 2022-10-07 CN CN202280006935.3A patent/CN117083291A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2023056913A1 (en) | 2023-04-13 |
CN117083291A (en) | 2023-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5813778B2 (en) | Immunomodulatory oligonucleotide (IRO) compounds for modulating immune responses based on toll-like receptors | |
JP2022532078A (en) | Compositions for skin and wounds and methods of their use | |
JP2015523853A (en) | Compositions and methods for modulating ATP2A2 expression | |
JP2016522674A (en) | Compositions and methods for regulating gene expression | |
JP2015523854A (en) | Compositions and methods for modulating SMN gene family expression | |
AR081295A1 (en) | TREATMENT OF DISEASES RELATED TO LIM HOMEOBOX 2 (LHX2) THROUGH THE INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO POLINUCLEOTIDES LHX2 | |
JP2017504589A5 (en) | ||
JP2023145532A (en) | Treatment of local skin hypotrophy conditions | |
BR112015016420B1 (en) | IMMUNORREGULATORY OLIGONUCLEOTIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF THE IRO COMPOUND OR PHARMACEUTICAL COMPOSITION | |
AR125351A1 (en) | COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF PNPLA3 | |
Wang et al. | Role of adenosine kinase inhibitor in adenosine augmentation therapy for epilepsy: a potential novel drug for epilepsy | |
JP5981141B2 (en) | Use of interleukin-22 for prevention and / or treatment of multiple organ dysfunction syndrome (MODS) | |
AR127858A1 (en) | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE ÓMICRON STRAIN OF SARS-CoV-2 | |
AR127311A1 (en) | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2 | |
WO2018232006A1 (en) | Polynucleotides encoding coagulation factor viii | |
JP2024511954A (en) | Treatment of myotonic dystrophy type 1 using peptide-oligonucleotide complexes | |
WO2015037001A1 (en) | Methods for inducing glucose uptake | |
EP2897633B1 (en) | Treatment of pain by inhibition of usp5 de-ubiquitinase | |
JP2017525675A5 (en) | ||
EP3755322A1 (en) | Targeting lipid metabolism and free fatty acid (ffa) oxidation to treat diseases mediated by resident memory t cells (trm) | |
WO2015162930A1 (en) | Method for improving protein expression, and composition for protein expression | |
KR101674122B1 (en) | Prevention or Treatment for ischemic stroke using miR-135-5p | |
TWI846697B (en) | Engineered extracellular vesicles and uses thereof | |
WO2022170396A1 (en) | Agents and methods for therapy and prophylaxis | |
JP2016020323A (en) | Composition for scaffold material for nerve regeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |